Improving the Lives of People with Neurodevelopmental Disabilities

Developing new therapies for debilitating neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells

Daybue™ (trofinetide)

World's **1st and only** approved therapy for **Rett** Syndrome[1]

Clinical development in **5 more** neurodevelopmental disorders, all with **Orphan Drug** designation, with no existing approved therapies[2].

no royalties payable to 3rd parties



Highlights

- DAYBUE™ (trofinetide) approved by US FDA as the 1st and only treatment for Rett syndrome
- Successful DAYBUE US launch, with CY2023 net sales of US$177m and CY2024 net sales guidance of US$370-420m
- Total economics to Neuren from global trofinetide partnership with Acadia up to US$1bn plus 10 to low 20s% royalties
- Accelerating Phase 2 development of NNZ-2591 in multiple indications, with positive results for Phelan-McDermid syndrome and Pitt Hopkins syndrome
- NNZ-2591 novel mechanism of action has many more potential applications
- Deep expertise in clinical development of orphan neurodevelopmental indications

Corporate

ASX Listing Code	NEU
Market Cap (15 Jul 2024)	A$2.6bn
Cash Balance (31 Mar 2024)	A$243m
Headquarters	Melbourne, Australia

[1] *Currently approved in US only*
[2] *Except growth hormone to treat some aspects of Prader-Willi*